<SEC-DOCUMENT>0001213900-24-054992.txt : 20240624
<SEC-HEADER>0001213900-24-054992.hdr.sgml : 20240624
<ACCEPTANCE-DATETIME>20240624080217
ACCESSION NUMBER:		0001213900-24-054992
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240624
FILED AS OF DATE:		20240624
DATE AS OF CHANGE:		20240624

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		241062148

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea020830901-6k_enlivex.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of: June 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>ENLIVEX THERAPEUTICS LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>14 Einstein Street, Nes Ziona, Israel 7403618</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 24, 2024, Enlivex Therapeutics Ltd., a
company organized under the laws of the State of Israel (&ldquo;Enlivex&rdquo;), issued a press release announcing that the first patient
has been dosed in an investigator-initiated, randomized, placebo-controlled Phase I/II trial evaluating Allocetra<SUP>TM</SUP> in up to
46 patients with thumb osteoarthritis. A copy of such press release is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated
herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 90%"><A HREF="ea020830901ex99-1_enlivex.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U>Press Release issued by Enlivex Therapeutics Ltd. on June 24, 2024.</U></FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">1</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enlivex Therapeutics Ltd.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oren Hershkovitz</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title:</P></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren Hershkovitz<BR>
Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: June 24, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">2</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea020830901ex99-1_enlivex.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON JUNE 24, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Enlivex Announces the Dosing of the First Patient
in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating Allocetra</B><SUP>TM</SUP> <B>in up to 46 Patients with Thumb Osteoarthritis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">First patient dosed with Allocetra<SUP>TM</SUP>
in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of people</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Thumb osteoarthritis currently has no FDA-approved
therapy and no effective long-term treatments </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ness-Ziona, Israel, June 24, 2024 (GLOBE NEWSWIRE)
-- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the &ldquo;Company&rdquo;), a clinical-stage macrophage reprogramming immunotherapy company,
today announced that the first patient has been dosed in an investigator-initiated, randomized, placebo-controlled Phase I/II trial evaluating
the efficacy and safety of Allocetra&trade; following injection into patients with basal thumb joint (first carpometacarpal (CMC) joint)
osteoarthritis, for which conventional therapies have failed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This investigator-initiated Phase I/II trial plans
to recruit up to 46 patients and is composed of two stages. The first stage is a safety run-in, open-label dose escalation phase to characterize
the safety and tolerability of an Allocetra<SUP>TM</SUP> injection in patients with osteoarthritis of the first basal thumb joint (first
CMC joint) of the target thumb to identify the dose for the randomized stage. The second stage is a double-blind, randomized, placebo-controlled
stage, which the Company expects to initiate following the completion of the safety run-in stage and selection of the safe and tolerable
dose. Up to 40 patients will be randomized in a 1:1 ratio for treatment with either Allocetra<SUP>TM</SUP> at the selected dose or placebo.
The primary safety endpoint will measure the frequency and severity of adverse events and serious adverse events, and the efficacy endpoints
will include assessments of change from baseline in pain and function for up to 12 months following treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;This is the first injection of Alloctera<SUP>TM</SUP>
into the basal thumb joint, and we are pleased with the swift enrollment of the first patient just a few weeks following regulatory approval
to initiate this trial. The injection of Alloctera<SUP>TM</SUP> into the patient&rsquo;s basal thumb joint was successfully completed
with no complications.&rdquo; stated Oren Hershkovitz, Ph.D., CEO of Enlivex.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ABOUT ALLOCETRA&trade;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Allocetra&trade; is being developed as a universal,
off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and
many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity
of the respective diseases. By restoring macrophage homeostasis, Allocetra&trade; has the potential to provide a novel immunotherapeutic
mechanism of action for life-threatening and life-debilitating clinical indications that are defined as &ldquo;unmet medical needs.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ABOUT BASAL THUMB OSTEOARTHRITIS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Osteoarthritis of the thumb is a chronic condition
causing pain, stiffness and occasional clicking and swelling in the joint at the base of thumb (also known as the carpometacarpal or CMC
joint). Simple daily tasks can become painful and difficult. The prevalence of thumb osteoarthritis increases substantially with age and
is more common in postmenopausal woman. The prevalence of radiographic base thumb OA was reported to be 5.8% and 7.3%, for 50-year-old
males and females, respectively, while the respective prevalence for 80-year-old male and female participants was reported as 33.1% and
39.0%<SUP>1</SUP>. The overall estimated symptomatic prevalence is up to 15% in adults over 30 years of age<SUP>2</SUP>. Osteoarthritis
of the thumb is a degenerative and progressive condition, and over time, conservative treatments and anti-inflammatory medication to reduce
pain and swelling start losing their effectiveness. Currently, there are no effective long-term treatments for this disease.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ABOUT ENLIVEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Enlivex is a clinical stage macrophage reprogramming
immunotherapy company developing Allocetra&trade;, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their
homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution
of life-threatening conditions. For more information, visit&nbsp;http://www.enlivex.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Safe Harbor Statement:&nbsp; This press release
contains forward-looking statements, which may be identified by words such as &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;projects,&rdquo;
&ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo;
&ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;suggests,&rdquo; &ldquo;has the potential to&rdquo; and other words of similar
meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical
experiments, the effectiveness of, and market opportunities for, ALLOCETRA<SUP>TM</SUP>&nbsp;programs. All such forward-looking statements
are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.&nbsp; Investors are cautioned
that forward-looking statements involve risks and uncertainties that may affect&nbsp;Enlivex&rsquo;s&nbsp;business and prospects, including
the risks that&nbsp;Enlivex&nbsp;may not succeed in generating any revenues or developing any commercial products; that the products in
development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval
or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show
substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the
forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of
clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage
trials. The development of any products using the ALLOCETRA<SUP>TM</SUP>&nbsp;product line could also be affected by&nbsp;a number of&nbsp;other
factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making,
the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary
rights held by competitors and other third parties.&nbsp; In addition to the risk factors described above, investors should consider the
economic, competitive, governmental,&nbsp;technological&nbsp;and other factors discussed in&nbsp;Enlivex&rsquo;s&nbsp;filings with the
Securities and Exchange Commission, including in the Company&rsquo;s most recent Annual Report on Form 20-F filed with the Securities
and Exchange Commission.&nbsp; The forward-looking statements contained in this press release speak only as of the date the statements
were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ENLIVEX CONTACT<BR>
Shachar Shlosberger, CFO<BR>
Enlivex Therapeutics, Ltd.<BR>
shachar@enlivexpharm.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Van Der Oest et al., 2021 - The prevalence of radiographic thumb base osteoarthritis: a meta-analysis.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Berger et al., 2015 - Management of osteoarthrosis of the thumb joints.&nbsp;</TD></TR></TABLE>
<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: left"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V , # 2(  A$! Q$!_\0
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3]*ZS@445XDY.3U/I*,(QCHC_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
